Target 2035 - an update on private sector contributions.
Saved in:
| Title: | Target 2035 - an update on private sector contributions. |
|---|---|
| Authors: | Ackloo S; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Antolin AA; ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL) L'Hospitalet del Llobregat Barcelona Catalonia Spain aantolin@idibell.cat., Bartolome JM; A Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com., Beck H; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Bullock A; Center for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk., Betz UAK; Merck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com., Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG Vienna Austria jark.boettcher@boehringer-ingelheim.com., Brown PJ; Structural Genomics Consortium, University of North Carolina at Chapel Hill USA peter.brown@unc.edu., Chaturvedi M; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Crisp A; Division of Cancer Therapeutics, The Institute of Cancer Research London SM2 5NG UK Alisa.crisp@icr.ac.uk., Daniels D; Foghorn Therapeutics 500 Technology Square, Suite 700 Cambridge MA 02139 USA DDaniels@foghorntx.com., Dreher J; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Edfeldt K; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se., Edwards AM; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Egner U; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com., Elkins J; Center for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk., Fischer C; Discovery Chemistry, Merck & Co., Inc. Boston Massachusetts 02115 USA christian_fischer@merck.com., Glendorf T; Research & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com., Goldberg S; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Hartung IV; Medicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany ingo.hartung@merckgroup.com., Hillisch A; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com., Homan E; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se., Knapp S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Köster M; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Krämer O; Boehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com., Llaveria J; A Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com., Lessel U; Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany uta.lessel@boehringer-ingelheim.com., Lindemann S; Merck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com., Linderoth L; Research & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com., Matsui H; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan hisanori.matsui@takeda.com., Michel M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se., Montel F; Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany florian.montel@boehringer-ingelheim.com., Mueller-Fahrnow A; Nuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com., Müller S; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Owen DR; Discovery Network Group, Pfizer Medicine Design Cambridge MA 02139 USA Dafydd.Owen@pfizer.com., Saikatendu KS; Global Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA kumar.saikatendu@takeda.com., Santhakumar V; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca., Sanderson W; Janssen Research & Development, Janssen Pharmaceutica N. V Beerse Belgium WSANDERS@its.jnj.com., Scholten C; Research and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany cora.scholten@bayer.com., Schapira M; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.; Department of Pharmacology & Toxicology, University of Toronto Toronto Ontario M5S 1A8 Canada., Sharma S; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Shireman B; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Sundström M; Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se., Todd MH; School of Pharmacy, University College London London WC1N 1AX UK mattoddchem@gmail.com., Tredup C; Institute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.; Structural Genomics Consortium, BMLS, Goethe University Frankfurt Frankfurt 60438 Germany susanne.mueller-knapp@bmls.de., Venable J; Janssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com., Willson TM; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA tim.willson@unc.edu., Arrowsmith CH; Structural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.; Princess Margaret Cancer Centre Toronto Ontario M5G 1L7 Canada. |
| Source: | RSC medicinal chemistry [RSC Med Chem] 2023 Mar 16; Vol. 14 (6), pp. 1002-1011. Date of Electronic Publication: 2023 Mar 16 (Print Publication: 2023). |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101759460 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8682 (Electronic) Linking ISSN: 26328682 NLM ISO Abbreviation: RSC Med Chem Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
